Wells Fargo Reiterates Buy Rating on Zymeworks Inc. (ZYME)
Wells Fargo maintains its buy rating for Zymeworks Inc., setting a price target of $37, a 44.81% upside from the current price.
Key Points
- Wells Fargo reiterated its buy rating on Zymeworks Inc. (ZYME) with a target price of $37 as of June 30, 2026.
- Wells Fargo's $37 price target implies 44.81% upside from Zymeworks Inc.'s ($ZYME) current $25.55 share price.
- Zymeworks stock traded near $26.59 on Wednesday, with a market cap of about $1.92 billion and a forward P/E ratio of 81.3.
- Other analysts like Evercore ISI Group and Stifel also maintain buy ratings, with targets as high as $58.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Wells Fargo reiterated its buy rating on Zymeworks Inc. (NasdaqGS: ZYME) on June 30, 2026, with a price target set at $37. This update comes as Zymeworks shares traded near $26.59 on Wednesday.
Wells Fargo vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Analysts Set New Price Targets
On June 30, 2026, Wells Fargo maintained its buy rating on Zymeworks Inc., setting a target price of $37. This follows previous ratings from other firms, including Evercore ISI Group, which also maintained a buy rating with a higher target of $48 on March 9, 2026. Stifel similarly kept a buy rating, setting a target of $47 on March 3, 2026. Overall, the consensus among analysts indicates a strong buy recommendation with an average target price of $38.5, based on 12 analyst opinions.
Zymeworks Inc. Stock Down 9.6%
Shares of Zymeworks Inc. traded near $26.59 on Wednesday. The company has a market cap of approximately $1.92 billion and a forward P/E ratio of 81.3. With a beta of 1.136, the stock has shown some volatility. Over the past 52 weeks, it has ranged from $11.51 to $29.75. The 50-day moving average is $25.14, while the 200-day moving average stands at $23.09. The company maintains a strong liquidity position with a current ratio of 10.82 and a quick ratio of 10.36.
$ZYME price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Other Institutional Activity in Zymeworks
Several institutional investors have adjusted their positions in Zymeworks. Rubric Capital Management LP increased its holdings by 1,250,000 shares, ending with 7,000,000 shares valued at about $175.28 million, marking a 21.7% increase. Perceptive Advisors LLC also grew its stake by 248,228 shares to a total of 3,510,078 shares valued at approximately $87.89 million, a 7.6% increase. Conversely, BlackRock, Inc. slightly trimmed its holdings by 41,660 shares, holding 4,553,888 shares worth around $114.03 million, a 0.9% decrease.
Insider Buying and Selling at Zymeworks Inc.
Recent insider activity at Zymeworks Inc. includes purchases by top executives. On May 13, 2026, Paul Schneider, the Executive Vice President and General Counsel, acquired 178,000 shares. On April 9, 2026, Scott Platshon, EVP and Chief Business Officer, bought 76,000 shares. These transactions did not involve planned sales under Rule 10b5-1 plans.
About Zymeworks Inc.
Zymeworks Inc. is a biotechnology company based in Middletown, Delaware, focusing on developing biotherapeutics for cancer, inflammation, and autoimmune diseases. Its innovative platforms include Azymetric multispecific antibody and Drug Conjugate platforms, among others. The company collaborates with major pharmaceutical firms like Jazz Pharmaceuticals and Merck, under the leadership of CEO Kenneth H. Galbraith.
Bottom Line
Wells Fargo's reiteration of a buy rating with a $37 target underscores continued confidence in Zymeworks Inc. Despite its current trading price, the company’s strategic partnerships and product pipeline remain of interest to investors. As always, it's important to remember that these analyst ratings reflect opinions and should be considered alongside other market data and individual investment goals.
Get Zymeworks Inc. alerts
New 13F filings, insider trades, and analyst moves on $ZYME, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.